Literature DB >> 7648707

Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis: a predominant role for the IgG3 subclass of ANCA.

A H Mulder1, C A Stegeman, C G Kallenberg.   

Abstract

To study ANCA-induced granulocyte activation in relation to disease activity in Wegener's granulomatosis (WG), serum samples taken from patients with WG at the time of active (n = 17) and inactive (n = 17) disease were analysed for their capacity to activate primed normal donor granulocytes. Compared with control sera (n = 6), the capacity of IgG fractions from patients with WG to induce the respiratory burst was significantly higher (P < 0.0001). Furthermore, the capacity to induce the respiratory burst significantly correlated with ANCA titre (r = 0.499, P = 0.003). IgG fractions from patients with active extensive disease induced the respiratory burst significantly more strongly than IgG fractions from patients with limited disease (n = 7) (P < 0.01) or patients during disease remission (n = 17) (P < 0.001). As ANCA-induced neutrophil activation is Fc-dependent and different IgG subclasses are involved in the interaction with various Fc receptors from neutrophils, we assessed changes in ANCA titre, total IgG and IgG subclass distribution of ANCA during active disease and remission in relation to the neutrophil-activating capacity of ANCA. Changes in capacity to activate granulocytes were related neither to changes in titre nor to changes in levels of total IgG, IgG1, IgG3, or IgG4 subclass of ANCA. However, changes in capacity to induce the respiratory burst were significantly related to changes in the relative amount of the IgG3 subclass of ANCA (P < 0.001), and not to changes in the relative amount of IgG1 or IgG4 subclass of ANCA. These data suggest that the increase in neutrophil-activating capacity of ANCA from inactive to active disease is, at least in part, based on the relative increase of the IgG3 subclass of ANCA that occurs during active disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7648707      PMCID: PMC1553249          DOI: 10.1111/j.1365-2249.1995.tb08343.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis.

Authors:  R Y Leavitt; A S Fauci; D A Bloch; B A Michel; G G Hunder; W P Arend; L H Calabrese; J F Fries; J T Lie; R W Lightfoot
Journal:  Arthritis Rheum       Date:  1990-08

2.  Association between active Wegener's granulomatosis and anticytoplasmic antibodies.

Authors:  J W Tervaert; F J van der Woude; A S Fauci; J L Ambrus; J Velosa; W F Keane; S Meijer; M van der Giessen; G K van der Hem; T H The
Journal:  Arch Intern Med       Date:  1989-11

Review 3.  Criteria for disease activity in Wegener's granulomatosis: a requirement for longitudinal clinical studies.

Authors:  C G Kallenberg; J W Tervaert; C A Stegeman
Journal:  APMIS Suppl       Date:  1990

4.  Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro.

Authors:  R J Falk; R S Terrell; L A Charles; J C Jennette
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

5.  Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis.

Authors:  B Nölle; U Specks; J Lüdemann; M S Rohrbach; R A DeRemee; W L Gross
Journal:  Ann Intern Med       Date:  1989-07-01       Impact factor: 25.391

6.  Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis.

Authors:  F J van der Woude; N Rasmussen; S Lobatto; A Wiik; H Permin; L A van Es; M van der Giessen; G K van der Hem; T H The
Journal:  Lancet       Date:  1985-02-23       Impact factor: 79.321

7.  Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.

Authors:  R J Falk; J C Jennette
Journal:  N Engl J Med       Date:  1988-06-23       Impact factor: 91.245

8.  Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre.

Authors:  J W Tervaert; M G Huitema; R J Hené; W J Sluiter; T H The; G K van der Hem; C G Kallenberg
Journal:  Lancet       Date:  1990-09-22       Impact factor: 79.321

9.  Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides.

Authors:  W Egner; H M Chapel
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

10.  Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils.

Authors:  R Goldschmeding; C E van der Schoot; D ten Bokkel Huinink; C E Hack; M E van den Ende; C G Kallenberg; A E von dem Borne
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

View more
  22 in total

Review 1.  Combination therapy in autoimmune disease: vasculitis.

Authors:  D Carruthers; P Bacon
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity.

Authors:  T Akamizu; S Ozaki; H Hiratani; H Uesugi; J Sobajima; Y Hataya; N Kanamoto; M Saijo; Y Hattori; K Moriyama; K Ohmori; K Nakao
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

Review 3.  Immunopathological aspects of systemic vasculitis.

Authors:  I M Bajema; E C Hagen; F Ferrario; E de Heer; J A Bruijn
Journal:  Springer Semin Immunopathol       Date:  2001

4.  Patients with systemic vasculitis have increased levels of autoantibodies against oxidized LDL.

Authors:  B P Swets; D A Brouwer; J W Tervaert
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

5.  Characterization of monoclonal antibodies to proteinase 3 (PR3) as candidate tools for epitope mapping of human anti-PR3 autoantibodies.

Authors:  Y M Van Der Geld; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 6.  Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.

Authors:  P Lamprecht
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

7.  Immunoglobulin subclass determines ability of immunoglobulin (Ig)G to capture and activate neutrophils presented as normal human IgG or disease-associated anti-neutrophil cytoplasm antibody (ANCA)-IgG.

Authors:  T Pankhurst; G Nash; J Williams; R Colman; A Hussain; C Savage
Journal:  Clin Exp Immunol       Date:  2011-03-10       Impact factor: 4.330

8.  Anti-proteinase-3 (PR3) antibodies (C-ANCA) recognize various targets on the human umbilical vein endothelial cell (HUVEC) membrane.

Authors:  M De Bandt; O Meyer; L Dacosta; C Elbim; C Pasquier
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

9.  Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates.

Authors:  Domenico Caccavo; Amelia Rigon; Antonio Picardi; Sara Galluzzo; Marta Vadacca; Giovanni Maria Ferri; Antonio Amoroso; Antonella Afeltra
Journal:  Clin Rheumatol       Date:  2004-12-09       Impact factor: 2.980

Review 10.  Endothelium-neutrophil interactions in ANCA-associated diseases.

Authors:  Lise Halbwachs; Philippe Lesavre
Journal:  J Am Soc Nephrol       Date:  2012-09       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.